Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 27Breast 5Thoracic 2Dermatologic 2Sarcoma 1Plasma cell 1Genitourinary 1

Conditions

Melanoma 135Lymphoma, T-Cell, Cutaneous 45Lymphoma, Non-Hodgkin 37Lymphoma, Follicular 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Large-Cell, Immunoblastic 34Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Mantle-Cell 33Lymphoma, B-Cell, Marginal Zone 33Burkitt Lymphoma 33Lymphoma 32Leukemia, Myeloid, Acute 32Hodgkin Disease 31Mycosis Fungoides 30Sezary Syndrome 29Multiple Myeloma 28Leukemia, Myeloid, Accelerated Phase 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 24Neoplasm Metastasis 24Leukemia, Myeloid, Chronic-Phase 24Leukemia 23Myelodysplastic Syndromes 22Lymphoma, Large-Cell, Anaplastic 22Congenital Abnormalities 22Blast Crisis 22Skin Neoplasms 20Immunoblastic Lymphadenopathy 20Myeloproliferative Disorders 19Recurrence 18

Interventions

pembrolizumab 6Paclitaxel 2Nivolumab 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Carboplatin 2veliparib 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1Topotecan 1Temozolomide 1Taxes 1Specimen Handling 1Ramucirumab 1Quality of Life 1Polymerase Chain Reaction 1Pemetrexed 1Patient Reported Outcome Measures 1Paracentesis 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Microarray Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Cyclophosphamide × Dermatologic × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡